| Gene Symbol |
ULBP2
|
| Entrez Gene |
80328
|
| Alt Symbol |
ALCAN-alpha, N2DL2, NKG2DL2, RAET1H
|
| Species |
Human
|
| Gene Type |
protein-coding
|
| Description |
UL16 binding protein 2
|
| Other Description |
NKG2D ligand 2|retinoic acid early transcript 1H
|
| Swissprots |
Q9BZM5 Q5VUN4
|
| Accessions |
AFP99107 AFP99108 AFP99109 AFP99110 AFP99113 AFP99114 AFP99115 AFP99116 AFP99117 AFP99118 EAW47777 EAW47778 Q9BZM5 AB052906 BAB61048 AF304378 AAK13082 AF321606 AAN39920 AK299895 BAG61739 AX772820 CAE06259 AY026825 AAK07688 AY358665 AAQ89028 BC034689 AAH34689 BG718474 NM_025217 NP_079493
|
| Function |
Ligand for the KLRK1/NKG2D receptor, together with at least ULBP1 and ULBP3. ULBPs activate multiple signaling pathways in primary NK cells, resulting in the production of cytokines and chemokines. Binding of ULBPs ligands to KLRK1/NKG2D induces calcium mobilization and activation of the JAK2, STAT5, ERK and PI3K kinase/Akt signal transduction pathway. In CMV infected cells, interacts with soluble CMV glycoprotein UL16. The interaction with UL16 blocked the interaction with the KLRK1/NKG2D receptor, providing a mechanism by which CMV infected cells might escape the immune system. UL16 also causes ULBP2 to be retained in the ER and cis-Golgi apparatus so that it does not reach the cell surface. {ECO:0000269|PubMed:11777960}.
|
| Subcellular Location |
Cell membrane; Lipid-anchor, GPI-anchor. Secreted.
|
| Tissue Specificity |
Expressed in various types of cancer cell lines and in the fetus, but not in normal tissues. {ECO:0000269|PubMed:11444831}.
|
| Top Pathways |
Natural killer cell mediated cytotoxicity
|
